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Adverse Drug Events (ADEs) are injuries resulting from medicine-related interventions.
They encompass medication errors, Adverse Drug Reactions (ADRs), and allergic reactions, etc. As a
matter of clarification, an ADE is a harm associated with any dose of medication, but an ADR is a harm
caused by a medication dose used commonly in prescription. Therefore, an ADR can be considered
a subtype of an ADE [1]. It is believed that ADEs may happen in hospitals, long-term care settings,
and outpatient clinics, but they are mainly preventable. Reducing the number of ADEs can improve
the quality and safety of healthcare systems, reduce healthcare costs and readmission rates, and lead
to higher satisfaction with healthcare services [2]. Therefore, preventive and pro-active interventions
on medicine prescribing, dispensing, administrating, and sufficient monitoring and reporting of ADEs
have been emphasized by international organizations. For instance, the World Health Organization
(WHO) in 2017 launched a global initiative to reduce avoidable medicine-associated harm by 50%
over the next five years across the globe. The WHO has also called all countries to devise priority
interventions for addressing the improper use of medicines with a high risk of harm, use of multiple
medicines by patients suffering from various health-related conditions, and transition of care in the
healthcare system [3]. In this respect, sensitizing the public with regard to the significance of ADEs
and developing evidence-based guidelines to ensure the monitoring of medicines are required. Also,
sharing knowledge and improving collaboration between multi-professional healthcare providers
with various geographic settings and languages can also help with this aim [4].
In line with the above-mentioned aim, the Special issue of “Patient Safety and Adverse Drug
Events in Medication Practice” opened the discussion on medicine management and called for article
submissions by international and multi-professional researchers. The rigorous peer-review process
managed by the journal’s editorial office led to the acceptance and publication of five articles authored
by researchers from Australia, India, Iran, Ireland, Malaysia, Norway, Pakistan, Saudi Arabia, and the
United Kingdom.
Briefly, they have developed knowledge on the healthcare providers’ role in pharmacovigilance,
barriers to the reporting and monitoring of ADEs/ADRs [5–7], pro re nata (PRN) as medicines
administration based on patients’ needs and related ADEs [8], and initiatives for the systematic
monitoring of ADEs/ADRs [9]. These studies have provided worthwhile findings with many
implications for education, practice, policy making, and future research. As concerns shared by
these studies, there is a need to develop the healthcare providers’ role and facilitate the reporting and
devising of monitoring systems of ADEs/ADRs.
For role development, besides physicians’ and pharmacists’ involvement in pharmacovigilance
activities [5–7], it is advised that nurses become central actors in medicine surveillance. Nurses
always have had a critical role in patient safety through their constant presence at the bedside and
collaboration with other healthcare providers and family caregivers [8,10,11]. Therefore, they are able
to detect medication issues that may be overlooked by other healthcare providers, and they can report
them to ensure patient safety.
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For the reporting and monitoring of ADEs/ADRs, for instance, the American Society of
Health-System Pharmacists (ASHP) has published some guidelines on ADRs surveillance, monitoring,
and reporting. It has asked that any ADRs program should incorporate evaluating, documenting,
and reporting of ADRs as well as providing feedbacks to healthcare professionals and patients, with the
aim of creating a positive change in medicine management [12]. Another example is the medicine
monitoring program, entitled the Adverse Drug Reaction Profile (ADRe), that has been introduced in
one the articles published in this Special Issue. The ADRe is on the basis of collaboration by nursing
professionals for multidisciplinary interventions. It provides nurses with a structured method for
medicine monitoring to identify ADRs with the aim of improving the health and wellbeing of patients.
Therefore, nurses complete the profile and pass highlighted problems to pharmacists and physicians
to inform a medication review. The multidisciplinary team evaluates the causes of problems identified,
and whether there is a need to change medicines [9,13].
In conclusion, the application of these on-going monitoring profiles in other settings requires
well-designed studies and the context-based adaptation of these profiles. Further studies are needed
to assess ADEs/ADRs monitoring profiles in terms of benefits taken by healthcare organizations and
healthcare professionals, identification of their weaknesses and strengths, incorporation of monitoring
profiles into risk-management initiatives, and their effects on the quality of healthcare services.
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